Drugs / NTR-441
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04941183 | Apr 2021 → Dec 2022 | COVID-19 | Neutrolis | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-29 | Neutrolis | Results Neutrolis Presented First-in-Human Proof-of-Concept Data Validating DNASE1L3-Mediated Neutrophil Extracellular Trap (NET) Clearance as a Therapeutic Approach in Autoimmunity at American College of Rheumatology Convergence 2025 neutrolis.com ↗
today announced positive first-in-human clinical data demonstrating that its DNASE1L3 analogue achieved rapid, multi-organ clinical improvement and robust target engagement consistent with its mechanism of NET degradation. |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTR-441 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04941183 ↗ |
| Route | Intravenous | “after single ascending IV infusion doses” NCT04941183 ↗ |